Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (CRTX) on May 19, 2022. The report details the completion of a previously announced merger with Novosteo Inc. and the departure of an executive officer. Note: While the request metadata mentions "Quince Therapeutics, Inc.", the filing text explicitly identifies the registrant as Cortexyme, Inc.
Key Financial Metrics and Transaction Details
- Merger Consideration: Approximately 6 million shares of Cortexyme common stock were issued to acquire Novosteo.
- Exchange Ratio: Each share of Novosteo capital stock was converted into 0.0911 shares of Cortexyme common stock.
- Option Conversion: Outstanding Novosteo options were converted into options to purchase an aggregate of 507,108 shares of Cortexyme common stock.
- Executive Severance: A cash severance payment of $339,000 (equivalent to nine months of base salary) was agreed upon for the departing Chief Legal and Administrative Officer.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
- Acquisition Completion: On May 19, 2022, Cortexyme completed the acquisition of Novosteo Inc., a Delaware corporation, pursuant to a Merger Agreement dated May 9, 2022.
- Executive Departure: Caryn McDowell, Chief Legal and Administrative Officer and Corporate Secretary, is departing effective July 8, 2022.
Outlook, Risks, and Unusual Items
- Separation Agreement Terms: The agreement with Ms. McDowell includes accelerated vesting of a restricted stock award issued on March 3, 2022, and an extension of the post-termination exercise period for vested stock options to twelve months following the departure date.
- Change in Control Provisions: If a change in control occurs within three months of the departure date, Ms. McDowell is entitled to additional cash severance, COBRA coverage, payment of the target annual bonus, and accelerated vesting of equity awards.
- Guidance: The filing text does not provide updated financial guidance or management commentary on future outlook.
Investor Verification Checklist
- Verify the exact number of shares issued and the impact on existing shareholder dilution.
- Review the full text of the Merger Agreement (Exhibit 2.1) for additional terms and conditions.
- Confirm the status of the replacement for the departing Chief Legal and Administrative Officer.
- Monitor future filings (Form 10-Q) for the full text of the Separation Agreement and any pro forma financial impacts of the Novosteo acquisition.